Histotype predicts the curative potential of radiotherapy: The example of ovarian cancers

Annals of Oncology

Volumn 22, Issue 2, 2011, Pages 341-347

  Swenerton, K D ^a,b   Santos, J L ^b   Gilks, C B ^b,c   Kobel M ^c,d   Hoskins, P J ^a   Wong, F ^a   Le, N D ^b  

^a The Gynecology Tumour Group   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

Adjuvant radiotherapy; Histology; Minimal residual disease; Outcomes; Ovarian cancer; Predictive factors

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; PACLITAXEL;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER DISEASE; BONE DISEASE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; ENDOMETRIOID CARCINOMA; ENTEROPATHY; FEMALE; GASTROINTESTINAL SYMPTOM; HEPATITIS; HISTOPATHOLOGY; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; MUCOSAL DISEASE; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; SKIN DISEASE; SOFT TISSUE CANCER; THROMBOCYTOPENIA;

EID: 79251588068     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq383     Document Type: Article

References (32)

1. Kobel M, Kalloger SE, Boyd N et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008; 5(12):e232.
2. Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol 2009; 40(9): 1213-1223. doi:10.1016/j.humpath.2009.04.017.
3. Fountain J, Trimble E, Birrer MJ. Summary and discussion of session recommendations. Gynecol Oncol 2006; 103 (2 Suppl 1): S23-S25.
4. Huang L, Cronin KA, Johnson KA et al. Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer? Cancer 2008; 112(10): 2289-2300. doi:10.1002/cncr.23425.
5. Paterson R. The Treatment of Malignant Disease by Radium and X-rays. 1st edition. London: Edward Arnold (Publishers) Ltd 1948.
6. Einhorn N, Trope C, Ridderheim M et al. A systematic overview of radiation therapy effects in ovarian cancer. Acta Oncologica 2003; 42(5/6): 562-566.
7. Nagai N, Inamine M, Hirakawa M et al. Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary. Gynecol Oncol 2007; 107: 469-473.
8. Swenerton KD, Hislop TG, Spinelli J et al. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol 1985; 65: 264-270.
9. Swenerton K. Prognostic indices in ovarian cancer: their significance in treatment planning. Acta Obstet Gynecol Scand 1992; 155 (Suppl): 67-74.
10. BCCA Cancer Management Guidelines. http://www.bccancer.bc.ca?HPI?CancerManagementGuidelines?Gynecology/default.htm. (19 July 2010, date last accessed).
11. Hoskins PJ, Swenerton KD, Wong F et al. Platinum plus cyclophosphamide plus radiotherapy is superior to platinum alone in 'high-risk' epithelial ovarian cancer (residual negative and either stage I or II, grade 3, or stage III, any grade). Int J Gynecol Cancer 1995; 5(2): 134-142.
12. Gilks CB, Ionescu DN, Kalloger SE et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 2008; 39(8): 1239-1251doi:10.1016/j.humpath.2008.01.003.
13. Dembo AJ, Davy M, Stenwig AE et al. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1990; 75: 263-273.
14. RTOG/EORTC late radiation morbidity scoring schema. http://www.rtog.org/members/toxicity/late.html. (19 July 2010, date last accessed).
15. Therneau T, Atkinson E. Technical Report Series No. 61, An introduction to recursive partition using the RPART routines. September 3, 1997. Rochester, Mayo Foundation.
16. Agresti A. Categorical Data Analysis. New York: Wiley 2002.
17. Cox DR, Oakes D. Analysis of Survival Data. 21st edn. Boca Raton: CRC Press; 1984.
18. Burnham KP, Anderson DR. Model Selection and Multimodel Inference: A Practical-Theoretic Approach. 2nd edn. New York: Springer-Verlag; 2002.
19. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: Wiley 2002.
20. Shelley WE, Starreveld AA, Carmichael JA et al. Toxicity of abdominopelvic radiation in advanced ovarian carcinoma patients after cisplatin/cyclophosphamide therapy and second-look laparotomy. Obstet Gynecol 1988; 71 (3 Pt 1): 327-332.
21. Hoskins PJ, Swenerton KD, Manji M et al. 'Moderate-risk' ovarian cancer (stage I, grade 2; stage II, grade 1 or 2) treated with cisplatin chemotherapy (single agent or combination) and pelvi-abdominal irradiation. Int J Gynecol Cancer 1994; 4 (4): 272-278.
22. Swenerton KD, Gilks B, Le N. Epithelial ovarian cancer without macroscopic residual: long-term, population-based outcomes. Proc Am Soc Clin Oncol 2004; 23: 460.
23. Hoskins PJ, O'Reilly SE, Swenerton KD et al. Ten-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy. J Clin Oncol 1992; 10 (10): 1561-1568.
24. Faught W, Le T, Fung Kee Fung M et al. Early ovarian cancer: what is the staging impact of retroperitoneal node sampling? J Obstet Gynaecol Can 2003; 25 (1): 18-21.
25. Suzuki M, Ohwada M, Yamada T et al. Lymph node metastasis in stage I epithelial ovarian cancer. Gynecol Oncol 2000; 79 (2): 305-308. doi:10.1006/gyno.2000.5951.
26. Fournier M, Stoeckle E, Guyon F et al. Lymph node involvement in epithelial ovarian cancer: sites and risk factors in a series of 355 patients. Int J Gynecol Cancer 2009; 19(8): 1307-1313.
27. Nomura H, Tsuda H, Susumu N et al. Lymph node metastasis in grossly apparent stages I and II epithelial ovarian cancer. Int J Gynecol Cancer 2010; 20: 341-345.
28. Fujiwara K, Suzuki S, Yoden E et al. Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy. Int J Gynecol Cancer 2002; 12(3): 250-256.
29. Takano M, Sugiyama T, Yaegashi N et al. The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study. Int J Gynecol Cancer 2009; 19(8): 1353-1357.
30. Mackillop WJ. Killing time: the consequences of delays in radiotherapy. Radiother Oncol 2007; 84: 1-4.
31. Olivotto IA, Lesperance ML, Truong PT et al. Intervals longer than 20 weeks from breast-conserving surgery to radiation therapy are associated with inferior outcome for women with early-stage breast cancer who are not receiving chemotherapy. J Clin Oncol 2009; 27(1): 16-23.
32. Kobel M, Kalloger SE, Santos JL et al. Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. Gynecol Oncol 2010; 116: 50-56.